Canaccord lowered the firm’s price target on Fractyl Health (GUTS) to $6 from $12 and keeps a Buy rating on the shares. The target was lowered after the firm updated its model for Q2 results and a subsequent equity offering while noting key timelines remain on track.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GUTS:
- Fractyl Health’s Earnings Call: Strategic Gains Amid Financial Challenges
- Fractyl Health Reports Q2 2025 Financial Results and Progress
- Fractyl Health, Inc.: Promising Developments and Strategic Focus Justify Buy Rating
- GUTS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Biotech Alert: Searches spiking for these stocks today